Regardless of the central role of DR4 during TRAIL-mediated apoptosis of tumor cells, there is some proof suggesting that DR4-C626G and -A1322G polymorphisms could be considered as the molecular risk factors for non-Hodgkin lymphoma (NHL) in human (83). This evidence concerns the gene TNFRSF10A and non-Hodgkin lymphoma.